The REMS Rollback and Its Impact on the T-cell Therapy Market Outlook for Hospitals

0
5

T-cell therapy is moving out of the lab and into mainstream oncology. Grand View Research puts the global T-cell therapy market at USD 7.1 billion in 2025, rising to USD 9.7 billion in 2026. It projects growth to USD 80.2 billion by 2033, a CAGR of 35.3% from 2026 to 2033.

This post covers where the money is, who is competing for it, where the science is heading, and what could slow things down.

Market Size & Projections

The figures point to a market that is changing from a research-led field into a commercially focused ecosystem. Three trends stand out:

  • CAR-T dominates. CAR-T therapies held more than 75.5% of market share in 2025, helped by a rising number of clinical studies and the involvement of large players.
  • Hematological malignancies lead on revenue. They accounted for about 46.5% of revenue in 2025, driven by CD19- and BCMA-targeted therapies in leukemia, lymphoma, and multiple myeloma.
  • North America leads, Asia Pacific is catching up. North America held roughly 47.5% of 2025 revenue, supported by a strong biotech ecosystem, clinical research infrastructure, and favorable reimbursement. Asia Pacific is expected to post the fastest CAGR through 2033. China is central to that growth and accounts for a substantial share of global CAR-T clinical trials.

By modality, the research segment held the largest share in 2025 because so many candidates are in preclinical and clinical development. The commercialized segment is expected to grow significantly as approvals accumulate and hospitals and cancer centers gain experience administering these treatments.

A regulatory change is helping that adoption. The U.S. FDA removed REMS requirements for approved BCMA- and CD19-directed CAR-T therapies, which lowers the administrative burden on treatment centers and makes access easier.

Go Deeper! Ask Prism AI about the Global - Market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.

Major Market Participants

The market is intensely competitive. Companies are expanding pipelines, building manufacturing capacity, and forming partnerships. Grand View Research profiles these players:

  • Novartis AG
  • Gilead Sciences Inc. (Kite Pharma)
  • Bristol Myers Squibb
  • Merck KGaA
  • Pfizer Inc.
  • Amgen
  • Cellectis
  • Adaptimmune Therapeutics plc
  • Autolus Therapeutics plc

Novartis and Gilead (Kite) keep a strong presence through their commercial CAR-T portfolios. Emerging companies are building next-generation platforms aimed at both blood cancers and solid tumors.

Recent deals show where the big players are placing their bets:

  • Manufacturing scale-up: In April 2024, Bristol Myers Squibb signed a capacity and supply agreement worth up to USD 380 million with Cellares, which uses an automated Cell Shuttle platform. In February 2026, Johnson & Johnson announced an investment of more than USD 1 billion in a cell therapy manufacturing facility in Pennsylvania, expected to create more than 500 jobs.
  • Pipeline expansion through M&A: AstraZeneca announced its acquisition of EsoBiotec in March 2025 to gain in vivo immune-cell engineering technology. Roche completed its acquisition of Poseida Therapeutics in January 2025, adding allogeneic CAR-T capabilities.
  • Commercial rollout: Adaptimmune expanded its authorized treatment center network for TECELRA to 20 U.S. centers by March 2025.

The analyst view in the report is that competitive advantage is shifting beyond product innovation. Manufacturing efficiency, supply chain reliability, and treatment accessibility are becoming the differentiators.

Want the full numbers? Download the Free Sample Report to see market data points, trend analyses, and forecasts.

Clinical & Technological Frontiers

Beyond CD19 and BCMA. Label expansion is already underway. In March 2024, Breyanzi became the first therapy of its kind approved in the U.S. for relapsed or refractory CLL and SLL.

TCR therapies for solid tumors. TCR-based therapies are expected to grow at the fastest CAGR of any therapy type. They can target intracellular tumor antigens that conventional CAR-T cannot reach, which makes them attractive for solid tumors. In August 2024, the FDA approved Adaptimmune's TECELRA, the first TCR-T therapy, for advanced synovial sarcoma.

Solid tumors as the next growth driver. Researchers are working on cell engineering, target identification, and combination approaches. The report points to growing numbers of clinical studies across multiple solid tumor indications.

In vivo CAR-T. Collaborations such as Kelonia Therapeutics with Johnson & Johnson (November 2025) and AstraZeneca's EsoBiotec deal show interest in engineering immune cells inside the body, which could simplify how these therapies are delivered.

Allogeneic and decentralized manufacturing. Roche's Poseida acquisition expands its allogeneic capabilities. Moffitt Cancer Center's expanded collaboration with Galapagos (April 2025) focuses on decentralized manufacturing and stem-like early memory T-cell products.

Structural Headwinds & Market Restraints

Grand View Research's public summary page has no dedicated restraints section. The challenges below come from what it does say, so the full report is the place to look for a quantified view.

  • Manufacturing scalability. Rising demand for CAR-T has pushed manufacturers to expand capacity and address scalability problems tied to autologous therapies, which are made individually for each patient. The size of the investments above reflects how pressing this is.
  • Solid tumor biology. Tumor infiltration, cellular persistence, and the immunosuppressive tumor microenvironment remain obstacles. Until they are overcome, growth will stay concentrated in hematological malignancies.
  • Resistance and adverse effects. The report notes that second- and next-generation CAR-T approaches aim to address these. It implies current-generation limitations still constrain broader use.
  • Access and administrative complexity. The REMS removal eased some of the burden on treatment centers. Even so, the report highlights treatment accessibility as a competitive differentiator, which suggests access is still uneven.
  • Production complexity. The report expects companies that reduce production complexity while broadening indications to strengthen their long-term position, a sign that complexity is still a drag on the industry.

Final Thoughts

A 35.3% CAGR reflects a field still early in its commercial life. Hematological malignancies and CAR-T fund the growth today. TCR therapies, solid tumor programs, in vivo engineering, and manufacturing automation will decide how much of the 2033 forecast is realized.

U.S. Healthcare Facility Mapping & Intelligence Platform! Cell therapy depends on qualified treatment centers. Explore the U.S. Healthcare Facility Mapping & Intelligence Platform to map and analyze the healthcare facilities where these therapies are delivered.

Pesquisar
Categorias
Leia mais
Networking
How Are Glucose Monitoring Devices Changing Diabetes Management and Patient Care?
According to the latest report published by Data Bridge Market Research, the Glucose...
Por kshdbmr 2026-10-07 10:54:11 0 636
Outro
Can a Decorative Mirror Instantly Refresh Your Living Space?
  A Small Change That Creates a Big Impact A Decorative mirror is one of the simplest ways...
Por theconvexmirrorcompa 2026-08-05 10:26:12 0 602
Religion
Car Rental Market: Service Providers and Growth Opportunities
"According to the latest report published by Data Bridge Market Research, the Car Rental...
Por shreymehta0077 2026-11-16 10:09:54 0 47
Outro
US Varicella Vaccine Market Size, Share, and Trends by 2034
The Varicella Vaccine Market is expanding as public health authorities, healthcare providers, and...
Por monicascott9133 2026-11-19 14:50:08 0 9
Health
Clinical Development Challenges in Tablet and Capsule Manufacturing
Tablets and capsules remain the gold standard in oral drug delivery, prized for their patient...
Por curexbio 2026-09-27 19:09:40 0 761